Table 3.
Specific Features of LR-M Nodules Based on Histologic Features and Nodules size on Contrast-enhanced US and CT/MRI.
| All lesion | CHC | ICC> | ||||||||||
| CEUS | Total (n = 94) |
<30 mm (n = 23) |
≥30 mm (n = 71) |
P value* |
Total (n = 34) |
<30 mm (n = 13) |
≥30 mm (n = 21) |
P value* |
Total (n = 56) |
<30 mm (n = 8) |
≥30 mm (n = 48) | P value* |
| Rim arterial phase hyperenhancement | 27 (29) | 2 (9) | 25 (35) | 0.015 | 8 (24) | 1 (8) | 7 (33) | 0.087 | 17 (30) | 1 (13) | 16 (33) | 0.325 |
| Early-onset washout (<60 s) |
82 (87) | 16 (69) | 66 (93) | 0.003 | 25 (74) | 7 (54) | 18 (86) | 0.041 | 53 (95) | 7 (88) | 46 (96) | 0.332 |
| Marked washout (<2 min) |
15 (16) | 2 (9) | 13 (18) | 0.274 | 3 (9) | 1 (8) | 2 (10) | 0.855 | 10 (18) | 1 (13) | 9 (19) | 0.669 |
| CT/MR | Total (n = 94) |
<30 mm (n = 23) |
≥30 mm (n = 71) |
P value* |
Total (n = 34) |
<30 mm (n= 13) |
≥30 mm (n = 21) |
P value* |
Total (n = 56) |
<30 mm (n = 8) |
≥30 mm (n = 48) | P value* |
| Rim arterial phase hyperenhancement | 56 (60) | 8 (35) | 48 (68) | 0.005 | 15 (44) | 4 (31) | 11 (52) | 0.380 | 39 (70) | 4 (50) | 35 (73) | 0.374 |
| Delayed central enhancement | 61 (65) | 12 (52) | 49 (69) | 0.141 | 19 (56) | 3 (23) | 16 (76) | 0.004 | 39 (70) | 5 (63) | 34 (71) | 0.953 |
| Peripheral washout | 32 (34) | 3 (13) | 29 (41) | 0.028 | 8 (24) | 2 (15) | 6 (29) | 0.444 | 22 (39) | 1 (13) | 21 (44) | 0.199 |
| MRI | Total (n =54) |
<30 mm (n = 13) |
≥30 mm (n = 41) |
P value* |
Total (n = 22) |
<30 mm (n = 8) |
≥30 mm (n = 14) |
P value* |
Total (n = 31) |
<30 mm (n = 5) |
≥30 mm (n = 26) | P value* |
| DWI targetoid restriction | 22 (41) | 3 (23) | 19 (46) | 0.245 | 5 (23) | 1 (13) | 4 (29) | 0.613 | 17 (55) | 2 (40) | 15 (58) | 0.636 |
| Gadoxetate disodium-enhanced MRI | Total (n= 17) | <30 mm (n = 4) |
≥30 mm (n = 13) |
P value* |
Total (n = 6) |
<30 mm (n = 3) |
≥30 mm (n = 3) |
P value* |
Total (n = 11) |
<30 mm (n = 1) |
≥30mm (n= 10) | P value* |
| Targetoid transitional phase appearance | 11 (65) | 3 (75) | 8 (62) | 1.000 | 4 (67) | 3 (100) | 1 (33) | 0.400 | 7 (64) | 0 (0) | 7 (70) | 0.364 |
| Targetoid hepatobiliary phase appearance | 13 (77) | 3 (75) | 10 (77) | 1.000 | 5 (83) | 3 (100) | 2 (67) | 1.000 | 8 (73) | 0 (0) | 8 (80) | 0.273 |
Data are numbers of observations, with percentages in parentheses. CT, computed tomography; MR, magnetic resonance imaging; CEUS, contrast enhanced ultrasound; ICC, intrahepatic cholangiocarcinomas; CHC, combined hepatocellular cholangiocarcinomas; *P values were determined with x2 test for comparison of the rate of feature occurring between the two subgroups divided according to the nodule size at the cut-off value of 30 mm.